Recommended Results

Producing Aseptic Nanoemulsions: Methods and Challenges


Nanoemulsions with precise particle size have, and will continue to have, a major impact on the pharmaceutical industry. Nanoemulsions are used to increase the bioavailability of drugs with low water solubility and control the drug delivery characteristics. For many aseptic nanoemulsions, particle size distribution is of great importance because aseptic filtration, an essential step in the production of most aseptic emulsions, requires particle size below 200 nm. 

Presented here are development, optimization and production challenges, such as scaling up, process integration and achieving the desired particle size of several sterile nanoemulsions. These formulations include: (a) vaccine adjuvant nanoemulsions currently used in flu vaccines, (b) cancer drug nanoemulsions, and (c) ocular nanoemulsions. The effects of the process parameters and the chemistry of the formulation in the final product quality will be highlighted. 

Key processing steps for aseptic nanoemulsions include pre-processing, high pressure/fixed geometry homogenization and aseptic filtration. Each step provides several parameters for controlling the quality of the processed material, including the level of energy dissipation in the microchannels of the homogenizer, the form of energy being dissipated (kinetic, turbulent, etc.), temperatures and residence times, and materials used for filtration, only to name a few. Finally, the chemistry and surface properties of the formulation components have a pivotal role in the final quality of the formulation.

Date: 2017-07-18, 14:00 - 13:00
Language: English
Trainer: Dr. Thomai Panagiotou

Dr. Panagiotou is an expert in nanomaterial processing, scale up and formulation. She is currently the President and CEO of Delphi Scientific, LLC. In the past, she has served as the CTO of the Materials Processing Group of IDEX Corporation, being responsible for the overall direction of the technology, new product development and collaborations with the industry and Academia. Dr. Panagiotou held various management positions (CTO, VP/R&D, etc.) with Microfluidics International. She serves as an expert witness in patent challenges involving large pharmaceutical companies. Dr. Panagiotou holds a MS and Ph.D. in Mechanical Engineering from Northeastern University in Boston. She led the development of award winning technologies (NANO 50TM International award), has co-authored over 60 and is a co-inventor of several patents.

Contact person and registration:
Hayley Gilbert
Tel.: +1 - 804 - 550 - 1051[at]